2 reports

  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.
  • COMPANION DIAGNOSTIC TEST - BREAST CANCER
  • COMPANION DIAGNOSTIC TEST - OVARIAN CANCER

Summary Chronix Biomedical, Inc. (Chronix Biomedical) is a molecular diagnostic company that develops blood tests for monitoring minimal residual disease in cancer patients. The company offers tests, which include second opinion tests and delta dot tests. Its second opinion tests include supplementary blood tests that can reduce...

  • Cancer
  • DNA
  • Pathology
  • United States
  • Chronix Biomedical, Inc.